At the center of the new study is a protein called SPICE1, short for spindle and centriole associated protein 1. SPICE1 has been implicated in tumor biology before, but its role in prostate cancer metastasis and, crucially, the way its abundance is controlled inside cells remained largely unknown. The researchers began by measuring SPICE1 levels in prostate cancer tissues and in bone metastatic lesions taken from patients. The results were striking: SPICE1 was markedly upregulated in prostate cancer tissue compared with normal tissue, and it was increased even further in lesions that had spread to bone. When the team analyzed clinicopathological data, they found that high SPICE1 expression was associated with aggressive disease features and poor prognosis, marking the protein as a potential red flag for the most dangerous forms of the illness.

To determine whether SPICE1 was merely a bystander or an active driver of metastasis, the researchers turned to laboratory experiments using two prostate cancer cell lines, PC3 and C42B. When they silenced SPICE1, the cells lost much of their malignant vigor. Proliferation slowed, migration and invasion were suppressed, and the cells were less able to undergo epithelial–mesenchymal transition, or EMT, the process by which cancer cells shed their rigid epithelial identity and become mobile, invasive, and resistant to therapy. These in vitro findings suggested that SPICE1 is not just correlated with aggressive disease but functionally required for it.

The team then moved from the dish to living systems, using two complementary animal models: subcutaneous xenografts, in which tumor cells are implanted under the skin, and an intra-arterial bone metastasis model that more faithfully reproduces how prostate cancer cells travel through the bloodstream and colonize bone. In both settings, silencing SPICE1 attenuated tumor growth and reduced bone metastasis. Together with the tissue data, the experiments establish SPICE1 as a pro-metastatic effector in prostate cancer, a molecule that tumor cells appear to depend on when they are establishing themselves in the skeleton.

Having shown what SPICE1 does, the researchers next asked how cancer cells keep it from being destroyed. Proteins inside cells are constantly being tagged for degradation by ubiquitin, a small molecular marker that condemns them to the cellular waste disposal system. The team used a battery of biochemical techniques, including co-immunoprecipitation, proximity ligation assays, site-directed mutagenesis, cycloheximide chase experiments, and dedicated ubiquitination and SUMOylation assays, to trace the fate of SPICE1. What emerged was an elegant two-step protection mechanism involving two other proteins: AURKA, a well-known cancer-associated enzyme, and TRIM28, a member of a family of proteins that attach SUMO, a tag that can shield proteins from ubiquitin-mediated destruction.

The first step of the mechanism involves phosphorylation, the attachment of a phosphate group to a protein. The researchers found that AURKA directly interacts with SPICE1 and phosphorylates it at a specific location, the amino acid serine 811. This single chemical modification proved to be the key that unlocks the rest of the pathway. Once SPICE1 is phosphorylated at serine 811, it becomes competent to recruit TRIM28, which functions as a SUMO E3 ligase, an enzyme that catalyzes the attachment of SUMO tags to target proteins. TRIM28 then SUMOylates SPICE1 at a second precise location, lysine 838. The SUMO tag at that site antagonizes ubiquitination, preventing SPICE1 from being marked for degradation. In effect, phosphorylation licenses SUMOylation, and SUMOylation stabilizes SPICE1, allowing the protein to accumulate to levels that support metastatic behavior.

The precision of this mechanism is what makes it scientifically compelling. Both modifications occur at defined amino acid positions, and the researchers demonstrated that disrupting either one collapses the protective chain. Without AURKA-mediated phosphorylation, SPICE1 cannot recruit TRIM28 efficiently. Without TRIM28-dependent SUMOylation at lysine 838, ubiquitination proceeds unchecked and SPICE1 is degraded. The team also performed rescue experiments: when they restored AURKA or TRIM28 in cells where SPICE1 had been silenced, the inhibitory effects on cell proliferation, migration, and invasion were partially reversed. This confirms that the AURKA/TRIM28/SPICE1 axis is not a side observation but a central regulatory circuit that drives the malignant phenotype.

Downstream of SPICE1 stabilization, the researchers identified changes that likely explain how the protein promotes cancer progression. Stabilized SPICE1 was accompanied by increased expression of FASN, the enzyme fatty acid synthase, which allows cancer cells to manufacture their own lipids and supports rapid growth. The team also observed activation of PI3K/AKT signaling, one of the most frequently hijacked growth pathways in human cancer, known for promoting cell survival, proliferation, and metabolic reprogramming. The authors note that these downstream changes likely contribute to the malignant phenotype but are secondary to the core AURKA/TRIM28/SPICE1 regulatory axis, which sits at the top of the cascade.

The clinical implications of the work are considerable. Because each node in the pathway is a defined molecular interaction, the axis offers multiple potential points of intervention. AURKA inhibitors already exist and are being evaluated in various cancers, and the new findings suggest that blocking AURKA could destabilize SPICE1 in prostate cancer cells, undermining their ability to survive and spread in bone. Alternatively, disrupting the SPICE1–TRIM28 interaction or the SUMOylation event itself could achieve a similar effect. The strong association between high SPICE1 expression and poor prognosis also raises the possibility that SPICE1 could serve as a biomarker, helping clinicians identify patients whose disease is most likely to metastasize to bone and who might benefit from more aggressive surveillance or targeted therapy.

As with any laboratory study, the path from mechanism to medicine will require further validation, including studies in larger patient cohorts and the development of strategies that can safely target the pathway in humans. The human tissue collection and animal experiments in the study were approved by the relevant ethics committees of the First Affiliated Hospital of Nanchang University, and the work was partially funded by a grant from the National Natural Science Foundation of China. Still, by revealing how phosphorylation, SUMOylation, and ubiquitination converge to keep a single metastasis-promoting protein alive, the study adds an important piece to the puzzle of why prostate cancer so relentlessly seeks out bone, and it hands researchers a detailed molecular map of where the next generation of therapies might strike.

Subject of Research: Post-translational regulation of SPICE1 by AURKA and TRIM28 in prostate cancer bone metastasis

Article Title: AURKA phosphorylation licenses TRIM28-dependent SUMOylation to stabilize SPICE1 in prostate cancer bone metastasis

Article References: Jiang, H., Tong, W., Wang, S., Xiong, X., Yao, G., Yang, F., Xu, Y., Liu, J., Xie, X., & Liu, Z. (2026). AURKA phosphorylation licenses TRIM28-dependent SUMOylation to stabilize SPICE1 in prostate cancer bone metastasis. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06396-7

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06396-7

Keywords: prostate cancer, bone metastasis, SPICE1, AURKA, TRIM28, SUMOylation, phosphorylation, ubiquitination, PI3K/AKT signaling, FASN, EMT, biomarker

The team’s starting point was the observation that osteoarthritis is driven largely by the progressive loss of the extracellular matrix, the network of collagens and proteoglycans that gives cartilage its resilience. When chondrocytes, the resident cells of cartilage, are exposed to inflammatory signals such as interleukin-1 beta, they ramp up enzymes that chew through this matrix, including members of the ADAMTS family. Current clinical options have shown limited efficacy in halting this degradation, which makes the search for the regulatory switches controlling matrix integrity a central goal of osteoarthritis research.

To model the disease in the laboratory, the researchers treated rat chondrocytes with 10 nanograms per milliliter of interleukin-1 beta for 24 hours. This well-established protocol reliably triggers an inflammatory, matrix-degrading phenotype. The team then measured the secretion of the inflammatory cytokines TNF-alpha and IL-6 by enzyme-linked immunosorbent assay, assessed the abundance of matrix components using alcian blue staining, and tracked the expression of candidate molecules with reverse transcription quantitative PCR, western blotting, and immunofluorescence staining. These complementary readouts allowed them to connect molecular changes at the level of genes and proteins to the physical integrity of the matrix the cells maintain.

The first key finding concerned AURKA, a kinase best known for controlling cell division but increasingly implicated in cartilage biology. When chondrocytes were stimulated with interleukin-1 beta, AURKA levels rose while the expression of both DOT1L and ITCH fell. This inverse relationship suggested a regulatory circuit in which ITCH normally restrains AURKA. Follow-up experiments using co-immunoprecipitation confirmed a physical interaction between ITCH and AURKA and demonstrated that ITCH promotes the ubiquitination of AURKA, tagging the kinase for destruction by the cell’s protein degradation machinery. When ITCH was abundant, AURKA was degraded; when ITCH dwindled under inflammatory conditions, AURKA accumulated.

The consequences for the cartilage matrix were striking. The experiments showed that ITCH, by promoting AURKA ubiquitination and degradation, attenuated the interleukin-1 beta-stimulated degradation of the extracellular matrix in rat chondrocytes. In other words, ITCH acts as a protective brake: its activity keeps AURKA levels in check, and low AURKA corresponds to a better-preserved matrix. This finding builds on earlier work by the same group, which had reported that the E3 ligase HECTD1 similarly targets AURKA for ubiquitination, and that inflammation disrupts that process to drive matrix degradation through enhanced translation of ADAMTS12. The new study adds a second E3 ligase, and an upstream epigenetic controller, to this emerging network.

That upstream controller is DOT1L, a histone methyltransferase that deposits the H3K79me3 mark on histone H3 at lysine 79. Unlike many histone modifications, H3K79 methylation occurs within the body of transcribed genes and is associated with active gene expression. Using chromatin immunoprecipitation, or ChIP, the researchers detected enrichment of both DOT1L and the H3K79me3 mark at the promoter region of the ITCH gene, indicating that DOT1L directly boosts ITCH transcription through this epigenetic modification. When DOT1L activity is reduced, as it is under inflammatory stimulation, H3K79me3 at the ITCH promoter drops, ITCH expression falls, AURKA escapes degradation, and matrix-degrading programs gain the upper hand.

To test whether reinforcing this axis could protect cartilage in a living organism, the team established a rat model of osteoarthritis induced by anterior cruciate ligament transection, a surgical model that mimics post-traumatic osteoarthritis in humans. Into the injured joints they injected a lentivirus engineered to drive overexpression of DOT1L. The joints were subsequently analyzed by hematoxylin and eosin staining, safranin O-fast green staining, and immunohistochemistry, standard histological approaches for assessing cartilage structure and proteoglycan content. All animal procedures were reviewed and approved by the Animal Ethics Committee of Hunan Provincial People’s Hospital.

The in vivo results supported the mechanistic model. Overexpression of DOT1L alleviated the cartilage degeneration caused by ligament transection, and molecular analysis revealed the expected downstream signature: the surgery-induced downregulation of ITCH was reversed, while the surgery-induced upregulation of AURKA and the matrix-degrading enzyme ADAMTS5 was blunted. In effect, elevating DOT1L re-engaged the epigenetic-to-proteolytic pathway that injury had silenced, preserving the cartilage that would otherwise have been lost. These findings identify the DOT1L/ITCH/AURKA axis as a key epigenetic and post-translational regulatory mechanism that protects against extracellular matrix degradation in osteoarthritis.

The study also fits into a broader and growing body of evidence that DOT1L is a guardian of cartilage health. Previous work has shown that mice deficient in Dot1l in cartilage are more susceptible to both spontaneous and post-traumatic osteoarthritis, and that hypoxia induces DOT1L in articular cartilage as a protective response. Research on inhibitors of the H3K79 demethylases KDM7A/B has likewise suggested that restoring H3K79 methylation can protect against osteoarthritis. Meanwhile, ITCH has previously been shown to limit post-traumatic osteoarthritis progression in mice by inhibiting macrophage polarization, and to improve lipopolysaccharide-induced chondrocyte injury by mediating ubiquitination of JAG1. The new study ties these threads together into a single coherent pathway, from chromatin marks through E3 ligase activity to kinase stability and matrix integrity.

The translational implications are considerable. If the DOT1L/ITCH/AURKA axis behaves similarly in human cartilage, strategies that boost DOT1L activity or H3K79me3 deposition, stabilize ITCH, or blunt AURKA accumulation in chondrocytes could slow or halt the matrix destruction that defines the disease. Because DOT1L inhibitors already exist and are being tested in oncology, the enzymology of this target is comparatively well understood, although any therapeutic repurposing would require careful evaluation of DOT1L’s roles in other tissues, where it participates in processes ranging from cardiac stress responses to cell proliferation and differentiation. The authors note that their findings collectively illuminate how epigenetic regulation and protein ubiquitination intersect to govern joint health, and the work was supported by the Research Project of Hunan Provincial Health Commission. For millions of people living with osteoarthritis, the study offers something that has been in short supply: a precisely mapped molecular circuit whose restoration in an animal model measurably preserved cartilage, and which now stands as a concrete starting point for designing drugs that attack the disease at its mechanistic roots rather than merely masking its symptoms.

Subject of Research: Epigenetic and post-translational regulation of cartilage extracellular matrix degradation in osteoarthritis via the DOT1L/ITCH/AURKA axis

Article Title: DOT1L-mediated H3K79me3 of ITCH promotes AURKA ubiquitination to suppress ECM degradation in osteoarthritis

Article References: DOT1L-mediated H3K79me3 of ITCH promotes AURKA ubiquitination to suppress ECM degradation in osteoarthritis. (n.d.). https://doi.org/10.1007/s00438-026-02514-z

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02514-z

Keywords: osteoarthritis, DOT1L, H3K79me3, ITCH, AURKA, ubiquitination, extracellular matrix, chondrocytes, epigenetics, cartilage degradation, ADAMTS5, interleukin-1 beta